I think the thanking of trial patients is from learning that some HIV positive patients in past trials have NASH. This likely was caused from the side effects from other HIV drugs and being on Leronlimab in trials for HIV may have also helped with their NASH. Not sure why the "cautiously" term was used other than they don't really know or can prove if Leronlimab is the reason for the NASH improvement in those patients?

The SP reaction again proves that this company is reguarded as a "throw what ever indecation against the wall and see what sticks" biotech. All the proof that this drug works as an HIV drug has been a back seat to the seemingly desperate new indications that pop up at an unheard of pace. Until they have a major partner putting a foundation under this and the BLA filed we don't look any different no mater the # or type of indication potential (as we have all been repeating).